Solvay to promote SmithKline Beecham's Famvir to OB-GYNs.
SOLVAY TO CO-PROMOTE SMITHKLINE BEECHAM FAMVIR TO OB-GYNs WITH 330 REPS, integrating calls for Famvir (famciclovir) into its promotions for women's health. "Our commitment to women's health, our ability to drive market share and our growing experience with alliances and cooperative ventures will be the platform for the success of the co-promotion," Solvay commented.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth